By Pooja Toshniwal PahariaOct 7 2022Reviewed by Danielle Ellis, B.Sc. In a recent study posted to the medRxiv* preprint server, researchers reviewed the duration and magnitude of the protective effect of previous severe acute respiratory syndrome coronavirus 2 infections and hybrid immunity against SARS-CoV-2 Omicron variant of concern infections and coronavirus disease 2019 severity.
Data were searched on Embase, MEDLINE, Cochrane Central Register of Controlled Trials, Web of Science, WHO COVID-19 database, Europe PubMed Central , and ClinicalTrials.gov databases between January 1, 2020, and June 1, 2022. In addition, the team included preprints identified during the period and published between June 1, 2022, and July 15, 2022. Additional records were identified based on recommendations of previous review authors and WHO’s solidarity 2 network investigators.
Related StoriesStudy designs included were traditional case-control, test-negative case-control, cohort, cross-sectional, randomized controlled trials , and non-RCTs. The team excluded case series, case reports, incomplete RCTs, reviews, duplicates, and preprints of articles that were eventually published. Additionally, studies that had no documentation of confirmed previous SARS-CoV-2 infections or days elapsed from the index infections until reinfections were excluded.
Among HE studies, 153 estimates were observed, of which 78 and 75 had moderate and serious RoB, respectively, with the longest follow-up assessments performed 11 months after prime vaccinations and four months after initial booster dose administration. Against both hospitalizations and COVID-19 severity outcomes, HE estimates involving prime vaccinations or initial booster dose administrations were consistent with >95% follow-up assessments.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Neonatal mice-based model established that allows for the transmission of clinical SARS-CoV-2 isolatesNeonatal mice-based model established that allows for the transmission of clinical SARS-CoV-2 isolates biorxivpreprint nyugrossman UMmedschool SARSCoV2 COVID19 coronavirus covid transmission
Source: NewsMedical - 🏆 19. / 71 Read more »
Can surveillance of SARS-CoV-2 be conducted through aircraft wastewater analysis?Can surveillance of SARS-CoV-2 be conducted through aircraft wastewater analysis? BangorUni MurdochUni StudentsNCL cardiffuni SARSCoV2 COVID19 coronavirus covid wastewater
Source: NewsMedical - 🏆 19. / 71 Read more »
Key biophysical attributes of a self-amplifying viral RNA vaccine developed for SARS-CoV-2Researchers used various analytical characterization techniques to determine the biophysical attributes of the Imperial College London self-amplifying viral RNA vaccine (IMP-1) developed for SARS-CoV-2.
Source: NewsMedical - 🏆 19. / 71 Read more »
Three-dimensional in vitro model to reproduce COVID-19-induced endothelial dysfunctionThree-dimensional in vitro model to reproduce COVID-19-induced endothelial dysfunction biorxivpreprint UTAustin COVID19 SARSCoV2 EndothelialDysfunction
Source: NewsMedical - 🏆 19. / 71 Read more »
Study suggests an immunological benefit of combining previous natural infection with vaccination against COVID-19 using a combination of different vaccine platformsStudy suggests an immunological benefit of combining previous natural infection with vaccination against COVID-19 using a combination of different vaccine platforms PLOSPathogens imperialcollege ImperialNHLI immunology infection
Source: NewsMedical - 🏆 19. / 71 Read more »
Probing SARS-CoV-2-positive plasma to identify potential factors correlating with mild COVID-19 in Ghana, West Africa - BMC MedicineBackground West Africa has recorded a relatively higher proportion of asymptomatic coronavirus disease 2019 (COVID-19) cases than the rest of the world, and West Africa-specific host factors could play a role in this discrepancy. Here, we assessed the association between COVID-19 severity among Ghanaians with their immune profiles and ABO blood groups. Methods Plasma samples were obtained from Ghanaians PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive individuals. The participants were categorized into symptomatic and asymptomatic cases. Cytokine profiling and antibody quantification were performed using Luminex™ multiplex assay whereas antigen-driven agglutination assay was used to assess the ABO blood groups. Immune profile levels between symptomatic and asymptomatic groups were compared using the two-tailed Mann-Whitney U test. Multiple comparisons of cytokine levels among and between days were tested using Kruskal-Wallis with Dunn’s post hoc test. Correlations within ABO blood grouping (O’s and non-O’s) and between cytokines were determined using Spearman correlations. Logistic regression analysis was performed to assess the association of various cytokines with asymptomatic phenotype. Results There was a trend linking blood group O to reduced disease severity, but this association was not statistically significant. Generally, symptomatic patients displayed significantly (p | 0.05) higher cytokine levels compared to asymptomatic cases with exception of Eotaxin, which was positively associated with asymptomatic cases. There were also significant (p | 0.05) associations between other immune markers (IL-6, IL-8 and IL-1Ra) and disease severity. Cytokines’ clustering patterns differ between symptomatic and asymptomatic cases. We observed a steady decrease in the concentration of most cytokines over time, while anti-SARS-CoV-2 antibody levels were stable for at least a month, regardless of the COVID-19 status. Conclusions The findin
Source: BioMedCentral - 🏆 22. / 71 Read more »